Lukasz Kwapisz
Gastroenterology · Miami, FLNPI 1366937351
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $899,421 of the $1,152,707 with a category attached, or 78.0%. 26 manufacturers reported payments, led by AbbVie at 48.9% of the total. Among gastroenterology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,244 payments — averaging $926.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$564K
- Johnson & Johnson$233K
- Lilly USA, LLC$225K
- E.r. Squibb & Sons, L.L.C.$105K
- Ferring Pharmaceuticals Inc.$5K
- Bristol Myers Squibb$5K
- plus $17K from 20 others
Across 10 payments — averaging $16,951 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$170K
What the payments were for
- Consulting fees$69,7996%
- Speaking & faculty fees$899,42178%
- Travel & lodging$153,06413%
- Food & beverage$30,3333%
- Education$900%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 623 | $564,040 |
| Johnson & Johnson | 224 | $232,604 |
| Lilly USA, LLC | 191 | $224,579 |
| E.r. Squibb & Sons, L.L.C. | 94 | $104,681 |
| Ferring Pharmaceuticals Inc. | 1 | $5,341 |
| Bristol Myers Squibb | 32 | $4,693 |
| Genentech USA, Inc. | 8 | $4,602 |
| Celltrion USA Inc. | 9 | $4,518 |
| Eli Lilly | 2 | $3,240 |
| Takeda Pharmaceuticals U.S.A., Inc. | 23 | $3,236 |
| Janssen Scientific Affairs, LLC | 7 | $625 |
| Pfizer | 5 | $98 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $93 |
| Merck | 5 | $75 |
| Sanofi | 1 | $36 |
| Braintree Laboratories, Inc. | 2 | $35 |
| Ardelyx, Inc. | 2 | $34 |
| Regeneron Healthcare Solutions, Inc. | 1 | $25 |
| Intercept Pharmaceuticals, Inc. | 1 | $22 |
| Romark Laboratories, LC | 1 | $22 |
| Boehringer Ingelheim | 1 | $22 |
| Boston Scientific | 1 | $19 |
| Ironwood Pharmaceuticals, Inc | 1 | $19 |
| Aimmune Therapeutics, Inc. | 1 | $18 |
| Vivus LLC | 1 | $16 |
| Redhill Biopharma Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,152,707 in reported general payments places this provider in the 95th percentile of 1,388 gastroenterology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 14 | $17,521 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 37 | $6,095 |
| Mesalamine | 19 | $3,386 |
| Omeprazole | 129 | $3,232 |
| Sucralfate | 20 | $3,192 |
| CholestyramineCholestyramine (With Sugar) | 20 | $1,384 |
| Famotidine | 32 | $588 |
| Pantoprazole Sodium | 33 | $471 |
| Ondansetron Hcl | 12 | $364 |
| Dicyclomine Hcl | 15 | $358 |
| Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg | 13 | $217 |
| Metronidazole | 11 | $110 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess | $564,040 | $17,52114 claims |
| Braintree Laboratories, Inc.Sutab | $35 | $6,09537 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,388 gastroenterology providers in Florida.
Other gastroenterology in Miami
- Joanna LopezMiami$670K
- Jerry MartelMiami$511K
- Andres GelrudMiami$208K
- Maria HernandezMiami$197K
- George SanchezMiami$117K
- Jodie BarkinMiami$101K
- Javier ParraMiami$68K
- Samuel GidayOrlando$2M
- Jennifer Seminerio-DiehlOrlando$1.1M
- Udayakumar NavaneethanSaint Petersburg$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.